HeartFlow

Redwood City, California, United States

Precision Medicine/Diagnostics AI / ML Cardiovascular DiseasePublic

AI-powered coronary artery disease diagnostic platform with IPO in 2025

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out HeartFlow on @MedStartr Today AI-powered coronary artery disease diagnostic platform with IPO in 2025. #CoronaryArteryDisease #MentalBehavioralHealth #PrecisionMedicineDiagnostics #AIML #CardiovascularDisease #MedMo #MedStartrVentures

https://www.medstartr.ai/s/8aj53x1828s

Get Involved in HeartFlow

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

How We Help

Problem Statement

To transform coronary artery disease (CAD) from a leading cause of death into a manageable condition.

Core Technology

AI-powered

Key Differentiators

AI-driven platform, non-invasive solution for CAD, creates personalized 3D models of coronary arteries, helps diagnose CAD, assess blood flow, quantify and characterize plaque, extensive clinical evidence, over 600 peer-reviewed publications.

Clinical Focus

Coronary Artery Disease (CAD)

Target Customers

Hospitals and healthcare providers

Product Stage

Company Info

Business Model: SaaS
Founded: 2007
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: www.heartflow.com/

Disease Areas

Coronary Artery Disease Mental Health

Technologies

Computational Fluid DynamicsNon-Invasive Diagnostics3D VisualizationAI & Machine Learning

Clinical & IP

🔬

Clinical Validation

Extensive clinical evidence with over 600 peer-reviewed publications.

🌐Website

MedStartr Engagement Score

Too Big!

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of HeartFlow?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.